Engineering human dendritic cells for tolerogenic gene therapy of type 1 diabetes

工程化人类树突状细胞用于 1 型糖尿病的耐受性基因治疗

• 批准号: nhmrc : GNT1162066
• 金额: $ 83.17万
• 依托单位国家: 澳大利亚
• 项目类别: Project Grants
• 财政年份: 2019
• 资助国家: 澳大利亚
• 起止时间: 2019-01-01 至 无数据
• 项目状态: 已结题
• 来源: https://researchdata.edu.au/engineering-human-dendritic-1-diabetes/1379209
• 关键词: Engineering; human; dendritic; cells; tolerogenic

Type 1 diabetes (T1D) afflicts more than 100,000 Australians and results from autoimmune destruction of insulin producing beta-cells. Insulin injections are required for survival, but T1D leads to substantial illness and reduced life expectancy. This project will test a newly-developed immunotherapeutic approach in a humanized mouse model of disease. Successful completion would accelerate the translation of this approach as a potential cure for T1D.

1 型糖尿病 (T1D) 困扰着超过 100,000 名澳大利亚人，其原因是产生胰岛素的 β 细胞的自身免疫性破坏。生存需要注射胰岛素，但 T1D 会导致严重疾病并缩短预期寿命。该项目将在人源化小鼠疾病模型中测试新开发的免疫治疗方法。成功完成将加速这一方法作为 T1D 潜在治疗方法的转化。